Euthymics Bioscience, Inc.

In positive new top-line Phase III results in the CNS space, Otsuka Pharmaceutical Co. Ltd. said its oral serotonin-norepinephrine-dopamine triple re-uptake inhibitor centanafadine hit its primary e

Now that Kymera Therapeutics Inc. has raised nearly $200m in venture capital to date – including a $102m series C round announced on 12 March – and entered into two collaborations with big pharma pa

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Below is a roundup of some of the most noteworthy recent transactions that occurred between Feb. 15 and M

Forest's acquisition of Clinical Data to get its just-approved antidepressant signals continuing strong demand. But better, and much needed, treatments remain elusive. Could antidepressants be on the